QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - NYSE:QGEN - NL0015002CX3 - Common Stock
48.6 USD
+0.05 (+0.1%)
48.93 USD
+0.33 (+0.68%)
Taking everything into account, QGEN scores 6 out of 10 in our fundamental rating. QGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making QGEN a very profitable company, without any liquidiy or solvency issues. QGEN has a decent growth rate and is not valued too expensively. These ratings could make QGEN a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
QGEN had positive earnings in the past year.
QGEN had a positive operating cash flow in the past year.
Each year in the past 5 years QGEN has been profitable.
QGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
QGEN has a better Return On Assets (6.41%) than 82.46% of its industry peers.
QGEN has a Return On Equity of 10.65%. This is amongst the best in the industry. QGEN outperforms 80.70% of its industry peers.
QGEN's Return On Invested Capital of 8.66% is amongst the best of the industry. QGEN outperforms 82.46% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 14.93%.
The 3 year average ROIC (7.25%) for QGEN is below the current ROIC(8.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROIC | 8.66% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
The Profit Margin of QGEN (18.30%) is better than 91.23% of its industry peers.
QGEN's Profit Margin has declined in the last couple of years.
QGEN has a better Operating Margin (26.86%) than 94.74% of its industry peers.
QGEN's Operating Margin has improved in the last couple of years.
The Gross Margin of QGEN (64.18%) is better than 85.96% of its industry peers.
In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
Compared to 1 year ago, QGEN has less shares outstanding
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.
2.2 Solvency
QGEN has an Altman-Z score of 4.14. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of QGEN (4.14) is better than 77.19% of its industry peers.
QGEN has a debt to FCF ratio of 2.91. This is a good value and a sign of high solvency as QGEN would need 2.91 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.91, QGEN belongs to the best of the industry, outperforming 80.70% of the companies in the same industry.
QGEN has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
QGEN has a Debt to Equity ratio of 0.25. This is comparable to the rest of the industry: QGEN outperforms 52.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Altman-Z | 4.14 |
ROIC/WACC1.11
WACC7.77%
2.3 Liquidity
QGEN has a Current Ratio of 1.61. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.61, QGEN is not doing good in the industry: 64.91% of the companies in the same industry are doing better.
A Quick Ratio of 1.35 indicates that QGEN should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.35, QGEN is doing worse than 66.67% of the companies in the same industry.
QGEN does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.20%, which is quite good.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.40% yearly.
The Revenue has been growing slightly by 5.15% in the past year.
QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.32% yearly.
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
3.2 Future
Based on estimates for the next years, QGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.78% on average per year.
Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.82% on average per year.
EPS Next Y8.61%
EPS Next 2Y8.32%
EPS Next 3Y8.49%
EPS Next 5Y8.78%
Revenue Next Year5.25%
Revenue Next 2Y5.5%
Revenue Next 3Y5.89%
Revenue Next 5Y7.82%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.68, QGEN is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 82.46% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.57. QGEN is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 18.64, which indicates a rather expensive current valuation of QGEN.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaper than 85.96% of the companies in the same industry.
QGEN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.09.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.68 | ||
| Fwd PE | 18.64 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 91.23% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, QGEN is valued cheaply inside the industry as 85.96% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.25 | ||
| EV/EBITDA | 14.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.4
PEG (5Y)2.46
EPS Next 2Y8.32%
EPS Next 3Y8.49%
5. Dividend
5.1 Amount
With a yearly dividend of 0.52%, QGEN is not a good candidate for dividend investing.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.55. QGEN pays more dividend than 87.72% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.52% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.32%
EPS Next 3Y8.49%
48.6
+0.05 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.95%
Inst Owner Change0%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.54B
Revenue(TTM)2.04B
Net Income(TTM)373.39M
Analysts74.17
Price Target52.39 (7.8%)
Short Float %3.13%
Short Ratio4.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.52% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.7%
Min EPS beat(2)-2.4%
Max EPS beat(2)7.8%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.51%
EPS beat(12)8
Avg EPS beat(12)3.69%
EPS beat(16)12
Avg EPS beat(16)5.44%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.16%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-0.41%
Revenue beat(16)7
Avg Revenue beat(16)0.85%
PT rev (1m)-0.82%
PT rev (3m)3.99%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.59%
EPS NY rev (1m)0.68%
EPS NY rev (3m)0.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.68 | ||
| Fwd PE | 18.64 | ||
| P/S | 5.17 | ||
| P/FCF | 21.25 | ||
| P/OCF | 15.61 | ||
| P/B | 3.01 | ||
| P/tB | 16.48 | ||
| EV/EBITDA | 14.67 |
EPS(TTM)2.35
EY4.84%
EPS(NY)2.61
Fwd EY5.36%
FCF(TTM)2.29
FCFY4.71%
OCF(TTM)3.11
OCFY6.41%
SpS9.41
BVpS16.17
TBVpS2.95
PEG (NY)2.4
PEG (5Y)2.46
Graham Number29.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROCE | 11.67% | ||
| ROIC | 8.66% | ||
| ROICexc | 10.87% | ||
| ROICexgc | 46.44% | ||
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% | ||
| FCFM | 24.31% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 94.78% | ||
| Cap/Sales | 8.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.61% | ||
| Profit Quality | 132.83% | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 4.14 |
F-Score8
WACC7.77%
ROIC/WACC1.11
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
EPS Next Y8.61%
EPS Next 2Y8.32%
EPS Next 3Y8.49%
EPS Next 5Y8.78%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
Revenue Next Year5.25%
Revenue Next 2Y5.5%
Revenue Next 3Y5.89%
Revenue Next 5Y7.82%
EBIT growth 1Y21.82%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.27%
EBIT Next 3Y22.23%
EBIT Next 5Y15.78%
FCF growth 1Y31.74%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y29.99%
OCF growth 3Y1.77%
OCF growth 5Y15.28%